Esperion (NASDAQ: ESPR) medicine Nexletol resulted noteworthy decline in cholesterol levels
The findings of combined data from four of the company’s Phase 3 studies were presented at the virtual American Heart Association Science Sessions 2020 on Friday. Esperion (NASDAQ: ESPR) told the Associated Press. Both trials found a substantial decrease of low-density cholesterol levels by NEXLETOL (bempedoic acid) Tablets by week 12 in set subgroups, including […]
